Historical record - last NADAC effective date: 1/15/2019
Product Information
DIOVAN HCT 320-12.5 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $11.7935 per EA under NDC 00078047134. Its NADAC has been published 321 times since Nov 28, 2013.
FDA first approved this application on Mar 6, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the valsartan and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 320 mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078047134
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/15/2019
Active Ingredients
HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA020818FDA Approved
3/6/1998
TE Code
AB
On Market Since
4/28/2006
Pharmacological Classes
Price Statistics
The NADAC for DIOVAN HCT 320-12.5 MG TAB has been published 321 times since Nov 28, 2013, and over the history we have for it it has risen 119.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.7935 per EA |
|---|---|
| All-time high | $11.7935 (Jan 15, 2020) |
| All-time low | $5.3813 (Nov 28, 2013) |
| Median price | $8.7884 |
| Average price | $8.9454 |
| Largest weekly change | +21.5% (Mar 14, 2018) |
| Weeks tracked | 321 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+119.2%
Last surveyed Jan 15, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DIOVAN HCT 320-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DIOVAN HCT 320-12.5 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $11.7935 per EA (NDC 00078047134), effective Jan 15, 2020.
How has the price of DIOVAN HCT 320-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for DIOVAN HCT 320-12.5 MG TAB has risen 119.2%. It has been tracked across 321 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DIOVAN HCT 320-12.5 MG TAB?
Since Nov 28, 2013, the NADAC for DIOVAN HCT 320-12.5 MG TAB has ranged from a low of $5.3813 (Nov 28, 2013) to a high of $11.7935 (Jan 15, 2020), with a median of $8.7884 per EA.
Are there cheaper alternatives to DIOVAN HCT 320-12.5 MG TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VALSARTAN-HYDROCHLOROTHIAZIDE 320-12.5 MG TAB, is $0.1911 per EA — about 98% below DIOVAN HCT 320-12.5 MG TAB.
Who manufactures DIOVAN HCT 320-12.5 MG TAB?
DIOVAN HCT 320-12.5 MG TAB (NDC 00078047134) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.